For glioma cells with PTEN mutation or deletion, an immunosuppressive TME evolved: the anti-cancerogenic immunity decreased, and resistance against T-cell lyses developed, together with a PDL-1 enhancement [35, 36]. This evidence concerns the gene PTEN and central nervous system cancer.